Based on poor prospects for profits and increased safety concerns of anemia drugs in general, Neose Technologies Inc. is discontinuing development of its erythropoiesis-stimulating agent (ESA), NE-180 (GlycoPEGylated erythropoietin). (BioWorld Today)